Astria Therapeutics Inc

Astria Therapeutics — Technical Presentation (December 2022)

30 slides from Astria Therapeutics's technical presentation, Dec 15, 2022

  1. Slide 1: STAR-0215 Phase 1a Trial Preliminary Results December 2022

    Astria STAR - 0215 Phase 1a Trial Preliminary Results December 2022 1 Confidential

  2. Slide 2: Forward-looking statements

    This presentation and various remarks we make during this presentation contain forward-looking statements of Astria Therapeutics, Inc. ("Astria," the "Company," "we", "our" or "us") within the meaning of applicable securities laws and regulations, including statements with respect to: the Company's

  3. Slide 3: Executive Summary

    Executive Summary Confidential 3 STAR - 0215 has shown early proof of concept for its target profile: long - acting preventative therapy for HAE, best - in - class PK profile, and dosing once every 3 months or less frequently Near - term clinical development plans ▪ Initiating Phase 1b/2 ALPHA - STA

  4. Slide 4: Hereditary Angioedema (HAE): A Rare, Disfiguring, and Potentially Life-Threatening Disease

    Hereditary Angioedema (HAE): A Rare, Disfiguring, and Potentially Life - Threatening Disease 4 1. Zuraw BL. N Engl J Med. 2008;359:1027 - 36. 2. Busse, P.J. et al. N Engl J Med. 2021; 132 - 150. 3. Lumry , W.R. Front Med. 2018; 5, 22. 4. Aygören - Pürsün , E. et.al. Orphanet j Rare Dis. 2018; 13:73.

  5. Slide 5: Plasma Kallikrein is an Established Target in HAE

    Plasma Kallikrein is an Established Target in HAE 5 HMWK = high molecular weight kininogen cHMWK = cleaved high molecular weight kininogen FXII = Factor XII FXIIa = activated Factor XII Confidential • In HAE, missing C1 inhibitor allows plasma kallikrein to process HMWK, which generates cleaved HMWK

  6. Slide 6: STAR-0215: Designed to Normalize Life with HAE

    STAR - 0215 : Designed to Normalize Life with HAE 6 1. If this application is nationalized in PCT member states ex - U.S., the term of any resulting patents would also be to 2042, exclu sive of any available term extensions. Astria wholly owns an international patent application directed to STAR - 0

  7. Slide 7: Long Half-Life and High Potency in Preclinical Studies

    STAR - 0215 Shows Long Half - Life and High Potency in Preclinical Studies Confidential 7 Natural Substrate (HMWK) Bradykinin Release Assay • STAR - 0215 inhibits plasma kallikrein at least as potently as lanadelumab • STAR - 0215 has a half - life of three times as long as lanadelumab in non - huma

  8. Slide 8: Phase 1a Trial Design

    STAR - 0215 Phase 1a Trial 8 • Randomized, double - blind 1 , placebo - controlled ▪ Healthy adult subjects ▪ 3 single ascending doses, delivered SC ▪ 6 active to 2 placebo randomization • Preliminary data include safety (84 days for 3 cohorts), PK and PD (84 days for cohorts 1 and 2; 56 days for co

  9. Slide 9: Phase 1a Designed to Demonstrate Early Proof of Concept

    Phase 1a Designed to Demonstrate Early Proof of Concept Confidential 9 Safety and tolerability profile: STAR - 0215 has shown a favorable safety profile and has been well - tolerated in healthy subjects Pharmacokinetics: Concentrations of STAR - 0215 are sustained at levels consistent with clinical

  10. Slide 10: STAR-0215: Preliminary Results

    fL-> / : Preliminary Results

  11. Slide 11: Phase 1a Baseline Demographics

    Phase 1a Baseline Demographics Confidential 11 1. Cohort 1 includes one subject who did not receive a full dose and is included in this analysis. PK and PD data from this subj ect will be excluded from the final analysis of this cohort. Results will be finalized after the end of the observation peri

  12. Slide 12: STAR-0215 Safety and Tolerability

    12 STAR - 0215 1 : • 8 (32%) subjects (STAR - 0215 or placebo) had related TEAEs • No SAEs and all related TEAEs were mild (Grade 1) and resolved. No Grade 2, 3, or 4 TEAEs. • 6 subjects had ISRs (all mild), most commonly site redness; no reports of pain Confidential TEAE= Treatment - emergent adver

  13. Slide 13: Results Show Potential Best-In-Class PK Profile

    13 Confidential Results Show STAR - 0215 has a Potential Best - In - Class PK Profile Results will be finalized after the end of the observation period 1. Chyung et al 2014. Weight (SD) in this dose cohort = 83.08 (9.459) kg. Mean dose is 249.2 mg SC. The comparison presented between STAR - 0215 and

  14. Slide 14: Rapid and Sustained Concentrations After Single Subcutaneous Doses

    Results Show Rapid and Sustained STAR - 0215 Concentrations After Single Subcutaneous Doses Confidential 14 Mean (SD) concentrations over time Results will be finalized after the end of the observation period STAR - 0215 : • Concentrations are proportional to dose • Long elimination phase consistent

  15. Slide 15: Modeling Supports Potential for Clinical Benefit with Infrequent Dosing

    Modeling Supports Potential for Clinical Benefit with Infrequent Dosing Confidential 15 1. Kaufman 1991 June 15. Blood 77(12): 2660 - 2667 2. Wang et al. Clin Transl Sci. 2020 Nov, 13(6): 1208 - 1216. doi 10 - 1111/ cts . 12806 Epub 2020 May 26. 3. Ecallantide EMA Assessment Report. 2011 June 23. EM

  16. Slide 16: Target Engagement is Assessed by Change in FXIIa-Activated cHMWK

    Target Engagement is Assessed by Change in FXIIa - Activated cHMWK Confidential 16 *p = 0.001; **p = 0.003 HMWK = high molecular weight kininogen cHMWK = cleaved high molecular weight kininogen FXIIa = activated Factor XII PLASMA KALLIKREIN INHIBITION BY STAR - 0215 Bradykinin MEASURED BY PD ASSAY c

  17. Slide 17: Sustained Inhibition of Plasma Kallikrein

    Results Show STAR - 0215 Achieves Sustained Inhibition of Plasma Kallikrein Confidential 17 No significant changes at any timepoints with placebo or 100 mg STAR - 0215 Results will be finalized after the end of the observation period 1. Wang et al. Clin Transl Sci. 2020 Nov, 13(6): 1208 - 1216. doi

  18. Slide 18: Results Show Early Proof of Concept of STAR-0215

    Safety and tolerability profile: STAR - 0215 has shown a favorable safety profile and has been well - tolerated in healthy subjects Pharmacokinetics: Estimated half - life is up to 110 days, keeping concentrations of STAR - 0215 sustained at levels consistent with clinical benefit in HAE for at leas

  19. Slide 19: Future Plans

    Future Plans

  20. Slide 20: ALPHA-STAR: A Phase 1b/2 Study in HAE

    20 ALPHA - STAR: A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics , Pharmacodynamics, and Immunogenicity of STAR - 0215 in Participants with Hereditary Angioedema. Trial Expect to Initiate Q1 2023, Initial Results Anticipated Mid - 2

  21. Slide 21: Proposed ALPHA-STAR Trial Design

    1. This cohort is expected to commence after a safety assessment of Cohort 1 Proposed ALPHA - STAR Trial Design Open - Label Single and Multiple Dose Phase 1b/2 POC Clinical Trial in HAE Single Dose, n =4 8 - week Run - In Planned Phase 2 Long - Term Open - Label Trial (LTOL) 450 mg, 6 - month follo

  22. Slide 22: ALPHA-STAR Optimizing Trial Conduct

    ALPHA - STAR Optimizing Trial Conduct 22 Confidential Multifactor Approach for Operational Success • No placebo group • Frequent remote contact and monitoring for support and engagement • Personalized assistance for visits Reduce Protocol Burden Optimize Site Activations Engage Communities • Global;

  23. Slide 23: Overview of the Expected Clinical Development Plan

    Overview of the Expected Clinical Development Plan Long - Term Open Label Trial Phase 3 Pivotal Trial in HAE Patients Initial results Q4 ‘23 Phase 1a, SAD - Healthy Subjects Initial results Mid ‘24 New cohorts Q1 ‘23 Initiate Q1 ‘23 Initiate H2 ‘23 ALPHA - STAR Phase 1b/2 POC Trial - HAE Patients PH

  24. Slide 24: HAE Market Insights

    —_—- -- Va oo / ; HAE Market Insights

  25. Slide 25: Global HAE Treatment Market is Substantial and Growing

    Global HAE Treatment Market is Substantial and Growing 1. Company - reported sales (Takeda, CSL Behring, Pharming, BioCryst ) 2. Analyst consensus forecasts compiled by Clarivate’s Cortellis , Astria company research and analysis. 3. Zanichelli A. Clin Transl Allergy. 2018: doi : 10.1186/s13601 - 01

  26. Slide 26: Approved and Late-Stage Preventative HAE Treatments

    Approved and Late - Stage Preventative HAE Treatments 26 *Efficacy quoted as reduction in mean attack rate vs placebo; data from respective products’ Prescribing Information 1,2,3,7 . 1. CINRYZE Prescribing Information, 2021. 2. HAEGARDA Prescribing Information, 2020. 3. TAKHZYRO Prescribing Informa

  27. Slide 27: Blinded Product Profile: Prescriber Market Research

    27 Blinded Product Profile Astria proprietary blinded qualitative market research study (2021) with 20 HAE treatment providers (screened for those treat ing at least 5 Type 1 & 2 HAE patients per year) Interviewed HAE Treatment Providers Were Highly Motivated to Prescribe a Product With STAR - 0215’

  28. Slide 28: All Surveyed HAE Patients Were Willing to Try a Product with Target Profile

    All Surveyed HAE Patients Were Willing to Try a Product with STAR - 0215’s Target Profile Confidential 28 Astria proprietary blinded quantitative market research study (2022) with 101 HAE patients recruited by HAEA patient organiza tio n. Patients were screened for those currently taking preventativ

  29. Slide 29: Early Proof of Concept and Expected Upcoming Milestones

    Early Proof of Concept for STAR - 0215 for HAE and Expected Upcoming Milestones Confidential 29 STAR - 0215 has shown early proof of concept for its target profile: long - acting preventative therapy for HAE, best - in - class PK profile, and dosing once every 3 months or less frequently • Full resu

  30. Slide 30: Slide 30

Astria Therapeutics — Technical Presentation (December 2022) on 6ix